Status:
ACTIVE_NOT_RECRUITING
Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders
Lead Sponsor:
Johns Hopkins University
Conditions:
Autoimmune Gastrointestinal Dysmotility
Eligibility:
All Genders
13+ years
Brief Summary
Gastrointestinal motility disorders represent a heterogeneous group of neuromuscular diseases of the enteric nervous systems. While autoimmune neuromuscular diseases of the central nervous system (CNS...
Detailed Description
Autoimmune gastrointestinal dysmotility (AGID) represents a subset of autoimmune disorders that affect the motor function of the gastrointestinal tract. It will often result in refractory gastrointest...
Eligibility Criteria
Inclusion
- Males and females \>13 years old.
- Patient referred to the GI Motility clinic for suspected enteric dysmotility based on chronic refractory gastrointestinal symptoms
- English proficiency and literacy sufficient to sign consent.
Exclusion
- Pregnancy documented with a serum or urine pregnancy test. If participants believe that they are pregnant, they will need to notify a study physician who will order a serum or urine test for pregnancy and remove them from the study if the test results come back positive.
Key Trial Info
Start Date :
April 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04872439
Start Date
April 22 2021
End Date
December 31 2026
Last Update
January 7 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224